Stock Events

Stock Events

AlloVir 

$9.81
23
+$0.15+1.55% Tuesday 20:00

Statistics

Day High
10.32
Day Low
9.55
52W High
24.15
52W Low
7.96
Volume
9,402
Avg. Volume
22,618
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

1MayExpected
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
-3.29
-2.21
-1.13
-0.05
Expected EPS
-1.17
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
0Revenue
-190.42MNet Income

Analyst Ratings

$19.50Average Price Target
The highest estimate is 20.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALVR. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that competes with AlloVir in the development of antiviral drugs, including treatments for viral infections which is a direct competition to AlloVir's focus on viral diseases.
Moderna
MRNA
Mkt Cap10.61B
Moderna is involved in the development of mRNA-based therapies and vaccines for infectious diseases, competing with AlloVir's viral infection treatments.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech competes in the space of developing treatments and vaccines for infectious diseases, directly competing with AlloVir's focus area.
Novavax
NVAX
Mkt Cap1.36B
Novavax is a competitor due to its focus on developing vaccines for infectious diseases, including COVID-19, which puts it in direct competition with AlloVir's infectious disease portfolio.
Pfizer
PFE
Mkt Cap140.15B
Pfizer develops and markets drugs and vaccines for a wide range of infectious diseases, competing with AlloVir in the infectious disease market.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments and vaccines for infectious diseases, competing with AlloVir's product pipeline.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes with AlloVir in developing monoclonal antibodies for the treatment of viral infections and other diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is involved in the development of treatments for viral diseases, among other areas, which puts it in competition with AlloVir.
Arbutus Biopharma
ABUS
Mkt Cap906.73M
Arbutus Biopharma is focused on discovering and developing antiviral therapies, making it a direct competitor to AlloVir in the antiviral space.

About

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Show more...
CEO
Mr. David L. Hallal
Employees
6
Country
US
ISIN
US0198181036

Listings

XNAS
US
KLRS
BOATS
BOATS
KLRS.BOATS

0 Comments

Share your thoughts

FAQ

What is AlloVir stock price today?▼
The current price of ALVR is $9.81 USD — it has increased by +1.55% in the past 24 hours. Watch AlloVir stock price performance more closely on the chart.
What is AlloVir stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange AlloVir stocks are traded under the ticker ALVR.
What is AlloVir revenue for the last year?▼
AlloVir revenue for the last year amounts to 0 USD.
What is AlloVir net income for the last year?▼
ALVR net income for the last year is -190.42M USD.
How many employees does AlloVir have?▼
As of April 01, 2026, the company has 6 employees.
In which sector is AlloVir located?▼
AlloVir operates in the Health Care sector.
When did AlloVir complete a stock split?▼
The last stock split for AlloVir was on January 16, 2025 with a ratio of 1:23.
Where is AlloVir headquartered?▼
AlloVir is headquartered in Waltham, US.